Santen Pharmaceutical Co.,Ltd.announced today that it has signed licensing agreements and an asset transfer agreement with two U.S. companies.

Santen has come to an out-licensing agreement with Visiox Pharmaceuticals, Inc. (hereafter Visiox) on the rights to product manufacturing, commercialization, and sales of OMLONTI, an eye drop for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Under the terms of the agreement, Santen grants Visiox exclusive rights in the U.S. for product manufacturing and commercialization of OMLONTI. Santen is eligible to receive sales milestone payments, as well as royalties on net U.S. sales of OMLONTI.

Santen has also made an asset transfer agreement with Harrow Health, Inc. (Nasdaq: HROW, hereafter Harrow Health) for Flarex(an eyedrop for ocular surface Inflammation associated with dry eye), Natacyn (an eyedrop for fungal blepharitis, conjunctivitis, and keratitis), TobraDex ST (an eyedrop for ocular inflammation with presence of risk of infection), ZERVIATE (an eyedrop for ocular itch associated with allergic conjunctivitis), FRESHKOTE (an eyedrop for temporary relief of symptoms of dry eye) and an out-licensing agreement on the rights for product manufacturing, commercialization, and sales of Verkazi (an eyedrop for vernal keratoconjunctivitis) and Cationorm Plus (an artificial tear). Under the terms of the agreement, Santen will sell and transfer Flarex, Natacyn, TobraDex ST, ZERVIATE, and FRESHKOTE and grant Harrow Health exclusive rights in the U.S. and Canada for product manufacturing and commercialization of Verkazia, and exclusive rights in Canada for product manufacturing and commercialization of Cationorm Plus. Santen will receive an upfront payment for the asset transfer and the out-licensing and is eligible for royalties on net sales of Verkazia and Cationorm Plus.

Santen will continue to strive to improve profitability from a company-wide perspective, secure investment in research and development that serves unmet medical needs, and further promote the development of a promising pipeline to maximize its contribution to patients.

 

Source:santen.com

Report Abuse